nodes	percent_of_prediction	percent_of_DWPC	metapath
Tasosartan—CYP3A4—bone cancer	0.987	1	CbGaD
Tasosartan—Irbesartan—JUN—bone cancer	0.00673	0.783	CrCbGaD
Tasosartan—Irbesartan—CYP3A4—bone cancer	0.00113	0.132	CrCbGaD
Tasosartan—Losartan—CYP3A4—bone cancer	0.00073	0.085	CrCbGaD
Tasosartan—AGTR2—G alpha (i) signalling events—GRM4—bone cancer	0.000345	0.0717	CbGpPWpGaD
Tasosartan—AGTR2—G alpha (i) signalling events—RGS1—bone cancer	0.000345	0.0717	CbGpPWpGaD
Tasosartan—AGTR1—Arf6 signaling events—GNA11—bone cancer	0.000288	0.0599	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—GRM4—bone cancer	0.000209	0.0434	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—GRM1—bone cancer	0.000181	0.0377	CbGpPWpGaD
Tasosartan—AGTR1—Arf6 signaling events—MET—bone cancer	0.000162	0.0337	CbGpPWpGaD
Tasosartan—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000153	0.0318	CbGpPWpGaD
Tasosartan—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000144	0.03	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—SMO—bone cancer	0.000127	0.0265	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—GRM4—bone cancer	0.000118	0.0245	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—RGS1—bone cancer	0.000118	0.0245	CbGpPWpGaD
Tasosartan—AGTR1—G alpha (q) signalling events—GRM1—bone cancer	0.000117	0.0243	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—GRM4—bone cancer	0.000107	0.0223	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—RGS1—bone cancer	0.000107	0.0223	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.000105	0.0218	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—GRM1—bone cancer	0.000102	0.0213	CbGpPWpGaD
Tasosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MMP2—bone cancer	0.000101	0.0211	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—GRM1—bone cancer	9.28e-05	0.0193	CbGpPWpGaD
Tasosartan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	8.26e-05	0.0172	CbGpPWpGaD
Tasosartan—AGTR1—Arf6 signaling events—EGFR—bone cancer	8.19e-05	0.0171	CbGpPWpGaD
Tasosartan—AGTR1—G alpha (q) signalling events—GNA11—bone cancer	7.53e-05	0.0157	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—GRM4—bone cancer	6.8e-05	0.0142	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	6.73e-05	0.014	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—GNA11—bone cancer	6.59e-05	0.0137	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	6.58e-05	0.0137	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—SMO—bone cancer	6.54e-05	0.0136	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—RGS1—bone cancer	6.32e-05	0.0132	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—GRM4—bone cancer	6.32e-05	0.0132	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—GNA11—bone cancer	5.98e-05	0.0125	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—IL3—bone cancer	5.97e-05	0.0124	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—GRM1—bone cancer	5.89e-05	0.0123	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—GRM1—bone cancer	5.48e-05	0.0114	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—IL3—bone cancer	5.42e-05	0.0113	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—SMO—bone cancer	4.15e-05	0.00864	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—SMO—bone cancer	3.86e-05	0.00804	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—GRM4—bone cancer	3.84e-05	0.008	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—RGS1—bone cancer	3.84e-05	0.008	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—GNA11—bone cancer	3.53e-05	0.00736	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—RGS1—bone cancer	3.49e-05	0.00726	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—GRM4—bone cancer	3.49e-05	0.00726	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—GRM1—bone cancer	3.33e-05	0.00693	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—ATF1—bone cancer	3.28e-05	0.00684	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—IL3—bone cancer	3.2e-05	0.00667	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—GRM1—bone cancer	3.02e-05	0.0063	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—TGFBR2—bone cancer	2.74e-05	0.0057	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—IGF1R—bone cancer	2.58e-05	0.00537	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—GNA11—bone cancer	2.15e-05	0.00447	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—SMO—bone cancer	2.13e-05	0.00444	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—RGS1—bone cancer	2.06e-05	0.00429	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—GRM4—bone cancer	2.06e-05	0.00429	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—GNA11—bone cancer	1.95e-05	0.00406	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—IL3—bone cancer	1.95e-05	0.00405	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	1.92e-05	0.00399	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—KIT—bone cancer	1.87e-05	0.00389	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—GRM1—bone cancer	1.79e-05	0.00372	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—IL3—bone cancer	1.77e-05	0.00368	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—BRAF—bone cancer	1.76e-05	0.00366	CbGpPWpGaD
Tasosartan—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	1.74e-05	0.00363	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—EGFR—bone cancer	1.7e-05	0.00355	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—MDM2—bone cancer	1.47e-05	0.00307	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—JUN—bone cancer	1.28e-05	0.00266	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—SMO—bone cancer	1.26e-05	0.00262	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—MMP9—bone cancer	1.25e-05	0.00259	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—GNA11—bone cancer	1.15e-05	0.0024	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—GSTP1—bone cancer	1.13e-05	0.00235	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	1.11e-05	0.00232	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—ATF1—bone cancer	1.07e-05	0.00223	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IL3—bone cancer	1.04e-05	0.00217	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—EGFR—bone cancer	1.01e-05	0.00209	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—TGFBR2—bone cancer	8.93e-06	0.00186	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—TP53—bone cancer	8.45e-06	0.00176	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IGF1R—bone cancer	8.4e-06	0.00175	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—NDUFA12—bone cancer	7.91e-06	0.00165	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—NT5C3A—bone cancer	6.56e-06	0.00136	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—KIT—bone cancer	6.09e-06	0.00127	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—BRAF—bone cancer	5.73e-06	0.00119	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—EGFR—bone cancer	5.55e-06	0.00116	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—MDM2—bone cancer	4.8e-06	0.000999	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—JUN—bone cancer	4.17e-06	0.000868	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—MMP9—bone cancer	4.06e-06	0.000845	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—EGFR—bone cancer	3.28e-06	0.000683	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ENO2—bone cancer	2.87e-06	0.000598	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—TP53—bone cancer	2.75e-06	0.000573	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—DHFR—bone cancer	2.66e-06	0.000555	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GNA11—bone cancer	2.49e-06	0.000518	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GSTP1—bone cancer	1.93e-06	0.000402	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PTGS2—bone cancer	1e-06	0.000208	CbGpPWpGaD
